NFKB1 and neoplasm: Canonical NFκB signaling via p65/RELA is known to promote carcinogenesis, enhance tumor cell survival and tumor progression, promote the development of metastatic disease, and induce resistance to standard of care chemotherapy regimens in TNBC37–42.